A Phase 3 interventional study of Benralizumab Arm A and Benralizumab Arm B in Moderate to Very Severe Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 409 sites in 17 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-06-13.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 16th largest by enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2014, is one of 76 in phase 3, and was the 146th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in France
Ages 18–99
AstraZeneca · Sites in India
Ages 18+
AstraZeneca · Sites in Argentina, Egypt, Mexico and 4 more countries
Ages 18+
AstraZeneca · Sites in Argentina, Colombia, Egypt and 9 more countries
Ages 30–80
By country, each count listing its studies:
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 57 · Phase 3 77 · Phase 4 19
First in 1999; this study’s year is marked. 14 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,656 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 137 across the 194 interventional studies, 976 across the 89 observational. Of the 264 that completed or were terminated, 127 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
9 of the studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT07315958AstraZenecaStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics | 2027-04-30 |
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
| NCT07307781AstraZenecaStudy of Patient With Frequent Exacerbations in Moscow | 2027-06-25 |
Add all 9 to your calendar (.ics) → With an account.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
This study's enrollment of 1,656 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Compared within Pulmonary Disease, Chronic Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases, Obstructive. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria:1.. 2.Subjects 40-85 y.o. 3.Moderate to very severe with Post Bronchodilator (BD) >20% and ≤65%. 4.≥2 moderate or ≥1 severe COPD exacerbation(s) required treatment or hospitalization within 2-52 weeks prior to Visit1. 5. Modified Medical Research Council (mMRC) score ≥1 at Visit 1. 6.Treatment with double or triple therapy throughout the year prior to Visit 1, constant 2 weeks prior to Visit 1. 7.Tobacco history of ≥10 pack-years. 8.Women of must use a highly effective form of from Visit 1 until 16 weeks after their last dose, and negative serum pregnancy test result at Visit 1. 9.Male subjects who are sexually active must be surgically sterile one year prior to Visit 1 or use an adequate method of contraception from the first Product (IP) dose until 16 weeks after their last dose. 10.Compliance with maintenance therapy during run-in ≥70%. 11. Blood eosinophils due to subject's stratification and cap for blood eosinophil levels.When any eosinophil cohort is full, subjects in the completed cohort will not be randomised and will be withdrawn from the study. Exclusion criteria: 1. pulmonary disease other than COPD or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab administered subcutaneously
Drug: Benralizumab Arm A
Benralizumab administered subcutaneously
Drug: Benralizumab Arm B
Placebo administered subcutaneously
Drug: Placebo
Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Placebo subcutaneously on study week 0 until study week 48 inclusive
Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL
A COPD exacerbation is defined by symptomatic worsening of COPD requiring: * Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or * Use of antibiotics; and/or * An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.
Time frame: From first IP to week 56
Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL
A COPD exacerbation is defined by symptomatic worsening of COPD requiring: * Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or * Use of antibiotics; and/or * An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.
Time frame: From first IP to week 56
Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL
Pre-bronchodilator FEV1 (L) is collected at Weeks 0, 4, 8, 16, 24, 32, 40, 48, and 56. Baseline is the last non-missing value with quality (acceptable or borderline quality grade) prior to the first dose of study treatment.
Time frame: First IP up to end of treatment Week 56
Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL
SGRQ is from 50-item PRO instrument. The SGRQ total score is expressed as a percentage of overall impairment, in which 100% means the worst possible health status and 0 indicates the best possible health status.
Time frame: First IP up to Week 56
Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL
CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential six-point response scales. A CAT total score is the sum of item responses. Score ranges from 0 to 40 with higher scores indicative of greater COPD impact on health status.
Time frame: First IP up to Week 56
Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL
The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity.
Time frame: First IP up to Week 56
Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS>=220/uL
The number of rescue medication inhalations and nebulizer treatments taken are recorded by the patient in the eDiary twice daily. Total rescue medication use is the sum of daytime and night-time use.
Time frame: First IP up to Week 56
Mean Change From Baseline in Proportion of Nights Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS>=220/uL
Change from baseline to week 56 in proportion of nights awakenings due to respiratory symptoms.
Time frame: First IP up to Week 56
Number of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS>=220/uL
The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Exacerbation event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an exacerbation event has occurred.
Time frame: Immediately following first IP up to week 56
Severity of EXACT-PRO for Patients With Baseline EOS>=220/uL
The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Severity for the study is the highest score of EXACT-PRO.
Time frame: Immediately following first IP up to week 56
Duration of EXACT-PRO for Patients With Baseline EOS>=220/uL
The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Calculation of event duration after identification of the following five parameters: 1) onset; 2) three-day rolling average; 3) maximum observed value; 4) threshold for improvement; and 5) recovery. That is, duration of the exacerbation is the time elapse between onset and recovery of the event.
Time frame: Immediately following first IP up to week 56
Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL
The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Annual EXACT-PRO exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.
Time frame: Immediately following first IP up to week 56
Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS>=220/uL
A COPD exacerbation is defined by symptomatic worsening COPD requiring systemic corticosteroids, antibiotics, or an inpatient hospitalization/death due to COPD.
Time frame: Immediately following first IP up to week 56
Time to First COPD Exacerbation
Time to first COPD exacerbation is from the randomization date to the first occurrence of COPD exacerbation
Time frame: Immediately following first IP up to week 56
Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL
Annual COPD exacerbations rate that result in ER or hospitalization is calculated by number of exacerbations resulting ER or hospitalization divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.
Time frame: Immediately following first IP up to week 56
Number of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS>=220/uL
Types of healthcare encounter: Hospitalisations (inc. intensive care and/or general care), Emergency department visits, Unscheduled outpatients visits, Home visits, Telephone calls, and ambulance transports.
Time frame: Immediately following first IP up to week 56
Duration of Study Treatment Administration
Duration of study treatment is calculated from first dose date to last dose date + 1 day.
Time frame: From first dose date to last dose date, 48 weeks per protocol.
Serum Concentration of Benralizumab
PK serum samples were collected pre-dose at each visit.
Time frame: Pre-first dose and pre-dose at end of treatment (week 56)
Immunogenicity of Benralizumab
Antidrug antibody (ADA) responses such as ADA prevalence, ADA incidence, ADA persistently positive counts, etc. were presented
Time frame: Pre-treatment until end of follow-up, week 60 per protocol.
| Milestone | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Started | 554 | 552 | 550 |
| Completed | 497 | 492 | 491 |
| Not completed | 57 | 60 | 59 |
| Withdrew: Eg., meds change, lack of efficacy, etc. | 6 | 9 | 7 |
| Withdrew: Death | 14 | 11 | 12 |
| Withdrew: Withdrawal by subject | 27 | 31 | 32 |
| Withdrew: Study specific withdrawal criteria | 0 | 0 | 1 |
| Withdrew: Incorrect enrolment | 1 | 1 | 0 |
| Withdrew: Severe non-compliance | 1 | 2 | 1 |
| Withdrew: Lost to follow-up | 4 | 2 | 3 |
| Withdrew: Adverse event | 4 | 4 | 3 |
A COPD exacerbation is defined by symptomatic worsening of COPD requiring: * Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or * Use of antibiotics; and/or * An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.
| Exacerbations per year | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL | 1.19 (1.04 to 1.36) | 1.03 (0.9 to 1.19) | 1.24 (1.08 to 1.42) |
A COPD exacerbation is defined by symptomatic worsening of COPD requiring: * Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or * Use of antibiotics; and/or * An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.
| Exacerbations per year | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL | 1.4 (1.19 to 1.64) | 1.32 (1.12 to 1.56) | 1.30 (1.11 to 1.52) |
Pre-bronchodilator FEV1 (L) is collected at Weeks 0, 4, 8, 16, 24, 32, 40, 48, and 56. Baseline is the last non-missing value with quality (acceptable or borderline quality grade) prior to the first dose of study treatment.
| Liter | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL | 0.014 ± 0.282 | 0.031 ± 0.294 | 0.010 ± 0.275 |
SGRQ is from 50-item PRO instrument. The SGRQ total score is expressed as a percentage of overall impairment, in which 100% means the worst possible health status and 0 indicates the best possible health status.
| Percentage | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL | -5.025 ± 14.677 | -6.723 ± 15.723 | -3.913 ± 15.039 |
CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential six-point response scales. A CAT total score is the sum of item responses. Score ranges from 0 to 40 with higher scores indicative of greater COPD impact on health status.
| Score on a scale | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL | -1.50 ± 6.89 | -2.43 ± 6.34 | -1.22 ± 6.53 |
The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity.
| Score on a scale | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL | -1.085 ± 5.273 | -1.354 ± 5.599 | -0.504 ± 5.674 |
The number of rescue medication inhalations and nebulizer treatments taken are recorded by the patient in the eDiary twice daily. Total rescue medication use is the sum of daytime and night-time use.
| Puffs/day | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS>=220/uL | -0.05 ± 3.21 | -0.27 ± 2.71 | 0.29 ± 3.03 |
Change from baseline to week 56 in proportion of nights awakenings due to respiratory symptoms.
| Proportion of nights | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Proportion of Nights Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS>=220/uL | -0.088 ± 0.310 | -0085 ± 0.283 | -0.049 ± 0.307 |
The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Exacerbation event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an exacerbation event has occurred.
| Participants | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| 0 | 180 | 184 | 179 |
| 1 | 101 | 103 | 99 |
| 2 | 42 | 49 | 34 |
| 3 | 25 | 14 | 15 |
| 4 | 17 | 13 | 14 |
| 5 | 5 | 6 | 5 |
| 6 | 4 | 4 | 2 |
| 7 | 6 | 1 | 5 |
| 8 | 1 | 1 | 4 |
| 9 | 1 | 2 | 1 |
| 10 | 0 | 1 | 0 |
The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Severity for the study is the highest score of EXACT-PRO.
| Score on a scale | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Severity of EXACT-PRO for Patients With Baseline EOS>=220/uL | 51.5 ± 11.30 | 50.8 ± 10.70 | 52.0 ± 11.20 |
The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Calculation of event duration after identification of the following five parameters: 1) onset; 2) three-day rolling average; 3) maximum observed value; 4) threshold for improvement; and 5) recovery. That is, duration of the exacerbation is the time elapse between onset and recovery of the event.
| Days | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Duration of EXACT-PRO for Patients With Baseline EOS>=220/uL | 82.2 ± 95.80 | 88.3 ± 105.30 | 101.7 ± 113.70 |
The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences "today". The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Annual EXACT-PRO exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.
| Exacerbations per year | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL | 1.14 (0.98 to 1.31) | 1.02 (0.88 to 1.19) | 1.04 (0.90 to 1.21) |
A COPD exacerbation is defined by symptomatic worsening COPD requiring systemic corticosteroids, antibiotics, or an inpatient hospitalization/death due to COPD.
| Participants | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS>=220/uL | 204 | 203 | 198 |
Time to first COPD exacerbation is from the randomization date to the first occurrence of COPD exacerbation
| Days | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Time to First COPD Exacerbation | 333 (273 to 400) | 329 (262 to 396) | 337 (261 to 390) |
Annual COPD exacerbations rate that result in ER or hospitalization is calculated by number of exacerbations resulting ER or hospitalization divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.
| Exacerbations per year | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL | 0.27 (0.20 to 0.35) | 0.15 (0.11 to 0.20) | 0.25 (0.19 to 0.33) |
Types of healthcare encounter: Hospitalisations (inc. intensive care and/or general care), Emergency department visits, Unscheduled outpatients visits, Home visits, Telephone calls, and ambulance transports.
| Participants | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Hospitalisations | 60 | 38 | 50 |
| Emergency Department Visits | 36 | 35 | 43 |
| Unscheduled Outpatient Visits | 219 | 236 | 202 |
| Home Visits | 18 | 22 | 18 |
| Telephone calls | 110 | 111 | 104 |
| Ambulance transports | 16 | 12 | 20 |
Duration of study treatment is calculated from first dose date to last dose date + 1 day.
| Days | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Duration of Study Treatment Administration | 302.4 ± 85.73 | 304.0 ± 82.40 | 302.5 ± 88.47 |
PK serum samples were collected pre-dose at each visit.
| ng/mL | Benralizumab 30 mg | Benralizumab 100 mg |
|---|---|---|
| Baseline | NA ± NA | NA ± NA |
| Week 56 | 219.45 ± 233.21 | 699.89 ± 243.20 |
Antidrug antibody (ADA) responses such as ADA prevalence, ADA incidence, ADA persistently positive counts, etc. were presented
| Participants | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| ADA prevalence | 53 | 64 | 39 |
| ADA incidence | 44 | 47 | 24 |
| Both base/post-baseline positive | 5 | 7 | 17 |
| Only post baseline positive | 43 | 46 | 20 |
| Only baseline positive | 5 | 11 | 2 |
| ADA persistently positive | 28 | 34 | 14 |
| ADA transiently positive | 15 | 12 | 6 |
| nAb prevalence | 43 | 43 | 25 |
| nAb incidence | 41 | 37 | 18 |
Collected over From the time the patient signed informed consent through the treatment period up to the follow-up visit (week 60).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benralizumab 30 mg | 15/554 (2.7%) | 151/554 (27.3%) | 293/554 (52.9%) |
| Benralizumab 100 mg | 11/552 (2%) | 177/552 (32.1%) | 318/552 (57.6%) |
| Placebo | 13/550 (2.4%) | 176/550 (32%) | 282/550 (51.3%) |
| Event | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 97/554 | 78/552 | 100/550 |
| PneumoniaInfections and infestations | 22/554 | 18/552 | 16/550 |
| Pneumonia bacterialInfections and infestations | 5/554 | 8/552 | 10/550 |
| Atrial fibrillationCardiac disorders | 4/554 | 8/552 | 2/550 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/554 | 1/552 | 5/550 |
| Acute myocardial infarctionCardiac disorders | 2/554 | 1/552 | 4/550 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/554 | 1/552 | 4/550 |
| Myocardial infarctionCardiac disorders | 4/554 | 3/552 | 1/550 |
| Coronary artery stenosisCardiac disorders | 0/554 | 0/552 | 3/550 |
| BronchitisInfections and infestations | 1/554 | 3/552 | 3/550 |
| Event | Benralizumab 30 mg | Benralizumab 100 mg | Placebo |
|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 83/554 | 95/552 | 66/550 |
| BronchitisInfections and infestations | 59/554 | 84/552 | 80/550 |
| Upper respiratory tract infectionInfections and infestations | 69/554 | 74/552 | 65/550 |
| Lower respiratory tract infectionInfections and infestations | 50/554 | 32/552 | 29/550 |
| Oedema peripheralGeneral disorders | 11/554 | 26/552 | 11/550 |
| HeadacheNervous system disorders | 21/554 | 26/552 | 20/550 |
| Back painMusculoskeletal and connective tissue disorders | 21/554 | 25/552 | 19/550 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 24/554 | 17/552 | 23/550 |
| Urinary tract infectionInfections and infestations | 23/554 | 22/552 | 15/550 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/554 | 14/552 | 21/550 |
| Age, Continuous(Year) | Benralizumab 30 mg | Benralizumab 100 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 65.9 ± 7.77 | 65.3 ± 8.05 | 65.2 ± 8.22 | 65.5 ± 8.01 |
| Sex: Female, Male(Participants) | Benralizumab 30 mg | Benralizumab 100 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 172 | 180 | 175 | 527 |
| Male | 382 | 372 | 375 | 1129 |
| Race/Ethnicity, Customized(Participants) | Benralizumab 30 mg | Benralizumab 100 mg | Placebo | Total |
|---|---|---|---|---|
| White | 496 | 493 | 488 | 1477 |
| Black or African American | 4 | 11 | 10 | 25 |
| Asian | 48 | 46 | 46 | 140 |
| Other | 6 | 2 | 6 | 14 |
Showing the first 100 of 409 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2014 to primary completion in Apr 2018, 45 months.
Results were first posted in Jun 2019, 1 year 2 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 45 months is above that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →